Bivalirudin and Desmopressin Market size is projected to growing at around 5.1% CAGR during the forecast period i.e., between 2024-2036. Increasing demand for bivalirudin is being driven by its application in the treatment of cancer and cardiovascular disease. In addition, rising incidences of cardiovascular diseases worldwide are expected to drive bivalirudin and desmopressin market growth during the forecast period. According to the World Health Organization, Cardiovascular disease is one of the leading causes of death worldwide. CVDs caused an estimated 17.9 million deaths in 2019, which accounted for 32% of all deaths worldwide. Furthermore, increasing demand for desmopressin owing to its use for nocturia and bedtime wetting is expected to drive global bivalirudin and desmopressin market growth. Desmopressin medicines have also been extensively used in conditions such as diabetes insipidus, which causes the body to produce excessive amounts of urine.
Bivalirudin is a synthetic residue compound that inhibits direct thrombin. Especially in people with severe chest pain or those undergoing angioplasty, it prevents the formation of blood clots. Also, heart attack patients who undergo percutaneous coronary intervention are treated with this drug. Likewise, desmopressin is an artificial replacement for vasopressin and acts by limiting the amount of water that is excreted in the urine. Moreover, awareness programs and initiatives regarding bedwetting and enuresis medical conditions are market trends expected to propel the demand for desmopressin during the forecast period. For instance, in September 2021, an organization launched a public awareness campaign to raise awareness about the problem of enuresis in children.
Growth Drivers
Challenges
Base Year |
2023 |
Forecast Year |
2024-2036 |
CAGR |
5.1% |
Regional Scope |
|
The global bivalirudin and desmopressin market is segmented and analyzed for demand and supply by application into percutaneous coronary intervention (PCI) procedures, percutaneous transluminal coronary angioplasty (PTCA) procedures, and others. Among these, the percutaneous coronary intervention (PCI) procedure segment is anticipated to capture the largest market size in the global bivalirudin and desmopressin market owing to the rising incidences of adverse cardiovascular (CVDs) and heart diseases among population. For instance, cardiovascular disease (CVD) was the leading cause of death in the United States in 2018, followed by stroke (17%), high blood pressure (11%), heart failure (9.5%), arteries diseases (3%), and other CVD (17.2%). PCI procedures are intended to reduce adverse cardiovascular diseases. PCI is further enhanced by antithrombotic and antiplatelet therapies as an adjunct to reduce MACE rates. This factor is expected to fuel the segment growth during the forecast period.
Our in-depth analysis of the global bivalirudin and desmopressin market includes the following segments:
By Application |
|
By End User |
|
Regionally, the global bivalirudin and desmopressin market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America is likely to dominate majority revenue share by 2036, as coronary artery disease (CAD) prevalence among the population resulted in increasing percutaneous coronary intervention (PCI) procedures in the region. It was observed that nearly 960,000 percutaneous coronary intervention procedures are performed each year in the United States. Percutaneous coronary intervention (PCI) also known as angioplasty, is a procedure to open a blocked or narrowing artery. Moreover, increasing cases of cardiovascular diseases and heart diseases in the region are expected to drive bivalirudin and desmopressin market growth during the forecast period. For instance, there were approximately 695,000 deaths caused by heart disease in the United States in 2020.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?